

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Miwako Kobayashi, MD¹; Jennifer L. Farrar, MPH¹; Ryan Gierke, MPH¹; Amadea Britton, MD^{1,2}; Lana Childs, MPH³; Andrew J. Leidner, PhD¹; Doug Campos-Outcalt, MD⁴; Rebecca L. Morgan, PhD⁵; Sarah S. Long, MD⁶; H. Keipp Talbot, MD⁷; Katherine A. Poehling, MD⁸; Tamara Pilishvili, PhD¹

In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV (PCV13) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Antibody responses to two additional serotypes included in PCV15 were compared to corresponding responses after PCV13 vaccination, and antibody responses to seven additional serotypes included in PCV20 were compared with those to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Merck Sharp & Dohme Corp.). On October 20, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years, and for adults aged 19–64 years with certain underlying medical conditions or other risk factors* who have not previously received a PCV or whose previous vaccination history is unknown. ACIP employed the Evidence to Recommendation (EtR) framework,† using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)§ approach to guide its deliberations regarding use of these vaccines. Before this, PCV13 and PPSV23 were recommended for use for U.S. adults

INSIDE

- 118 Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
- 125 COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
- 132 COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021
- 139 Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- 146 Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
- 153 Notes from the Field: Increased Incidence of Fentanyl-Related Deaths Involving *para*-Fluorofentanyl or Metonitazene — Knox County, Tennessee, November 2020–August 2021
- 157 QuickStats

Continuing Education examination available at https://www.cdc.gov/mmwr/mmwr_continuingEducation.html



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

and the recommendations varied by age and risk groups. This was simplified in the new recommendations.

PPSV23 has been recommended for use in the United States since the 1980s for adults aged ≥65 years and for younger adults with underlying conditions that increase their risk for pneumococcal disease (1). PCV13 was first recommended for use in U.S. children in 2010, and indirect effects from its use in children reduced PCV13-type pneumococcal disease incidence in all adult groups (Figure). In 2012, ACIP recommended administration of PCV13 in series with PPSV23 for adults with immunocompromising conditions, cerebrospinal fluid leaks, or cochlear implants (2), and in 2014, the recommendation was extended to all adults aged ≥65 years (3). On the basis of review of accrued evidence, the PCV13 recommendation was changed in 2019 to shared clinical decision-making for adults aged ≥65 years without an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant. The recommended pneumococcal vaccine doses and intervals between doses differ by age and underlying conditions, making adult pneumococcal vaccine recommendations complicated.

† Immunocompromising conditions are defined as chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, HIV, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplant, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies.

Recent systematic reviews continue to support the effectiveness of PCV13 against invasive pneumococcal disease (IPD)** and pneumococcal pneumonia among adults (4,5). Whereas effectiveness of PPSV23 against IPD has been demonstrated, data on effectiveness against pneumococcal pneumonia were considered to be inconsistent (3); recent observational studies reported 21%–46% effectiveness against PPSV23-type pneumococcal pneumonia when PPSV23 was given <5 years before illness onset (6–8). Nevertheless, older adults and adults with chronic medical conditions^{††} or immunocompromising conditions, cerebrospinal fluid leaks, or cochlear implants (certain underlying conditions) remain at increased risk for pneumococcal disease, accounting for >90% of adult IPD cases in 2019 (Active Bacterial Core surveillance, unpublished data, 2021).

During February–October 2021, ACIP reviewed the epidemiology of pneumococcal disease and considerations for use of PCV15 and PCV20 in adults. The ACIP Pneumococcal

** The case definition used by CDC's Active Bacterial Core surveillance is isolation of *S. pneumoniae* from a normally sterile site or pathogen-specific nucleic acid in a specimen obtained from a normally sterile body site using a validated molecular test. <https://www.cdc.gov/abcs/methodology/case-def-ascertain.html>

†† Alcoholism; chronic heart, liver, or lung disease; cigarette smoking; or diabetes mellitus.

The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2022;71:[inclusive page numbers].

Centers for Disease Control and Prevention

Rochelle P. Walensky, MD, MPH, *Director*

Debra Houry, MD, MPH, *Acting Principal Deputy Director*

Daniel B. Jernigan, MD, MPH, *Deputy Director for Public Health Science and Surveillance*

Rebecca Bunnell, PhD, MEd, *Director, Office of Science*

Jennifer Layden, MD, PhD, *Deputy Director, Office of Science*

Leslie Dauphin, PhD, *Acting Director, Center for Surveillance, Epidemiology and Laboratory Services*

MMWR Editorial and Production Staff (Weekly)

Charlotte K. Kent, PhD, MPH, *Editor in Chief*

Jacqueline Gindler, MD, *Editor*

Paul Z. Siegel, MD, MPH, *Associate Editor*

Mary Dott, MD, MPH, *Online Editor*

Terisa F. Rutledge, *Managing Editor*

Teresa M. Hood, MS, *Lead Technical Writer-Editor*

Leigh Berdon, Glenn Damon, Soumya Dunwirth, PhD,

Tiana Garrett-Cherry, PhD, MPH, Srila Sen, MA,

Stacy Simon, MA, Morgan Thompson,

Technical Writer-Editors

Martha F. Boyd, *Lead Visual Information Specialist*

Alexander J. Gottardy, Maureen A. Leahy,

Julia C. Martinroe, Stephen R. Spriggs, Tong Yang,

Visual Information Specialists

Quang M. Doan, MBA, Phyllis H. King,

Terraye M. Starr, Moua Yang,

Information Technology Specialists

Ian Branam, MA,

Acting Lead Health Communication Specialist

Shelton Bartley, MPH, Leslie Hamlin,

Lowery Johnson, Amanda Ray,

Health Communication Specialists

Will Yang, MA,

Visual Information Specialist

MMWR Editorial Board

Timothy F. Jones, MD, *Chairman*

William E. Halperin, MD, DrPH, MPH

Jewel Mullen, MD, MPH, MPA

Jeff Niederdeppe, PhD

Celeste Philip, MD, MPH

Patricia Quinlisk, MD, MPH

Patrick L. Remington, MD, MPH

Carlos Roig, MS, MA

William Schaffner, MD

Nathaniel Smith, MD, MPH

Morgan Bobb Swanson, BS

Abigail Tumpey, MPH

Vaccines Work Group (Work Group) evaluated the quality of evidence for PCV15 and PCV20 immunogenicity and safety using the GRADE approach.^{§§} Using the EtR framework,^{¶¶} the Work Group reviewed relevant scientific evidence regarding the benefits and harms of PCV15 and PCV20 use among adults aged ≥65 years and younger adults with certain underlying conditions. Within the EtR framework, ACIP considered the importance of the public health problem, benefits and harms, target populations' values and preferences, resource use, equity, acceptability, and feasibility for PCV15 or PCV20 use. After a systematic review of the literature, the Work Group defined critical outcomes and used GRADE to assess certainty of evidence rated on a scale of 1 (high certainty) to 4 (very low certainty) (9).

^{§§} <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV20-risk-based.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-risk-based.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV20-age-based.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-based.html>

^{¶¶} <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV20-risk-based-et्र.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV20-age-based-et्र.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-risk-based-et्र.html>; <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-based-et्र.html>

Evidence


Pneumococcal disease incidence in adults. During 2018–2019, the incidence of all IPD in adults aged ≥65 years was 24 per 100,000 population (Figure), and PCV13 serotypes accounted for 27% of cases; additional serotypes unique to PCV15,^{***} PCV20,^{†††} and PPSV23^{§§§} caused 15%, 27%, and 35% of IPD, respectively. In adults aged 19–64 years with certain underlying conditions, PCV13 serotypes accounted for 30% of IPD; serotypes unique to PCV15, PCV20, and PPSV23 caused 13%, 28%, and 43% of IPD, respectively. Estimates of pneumococcal pneumonia incidence are more variable. Annual incidence among U.S. adults aged <65 and ≥65 years hospitalized with community-acquired pneumonia was estimated at 126–422 and 847–3,365 per 100,000, respectively, during 2010–2016 (10). In a multisite study of adults hospitalized with community-acquired pneumonia, 4.6% of cases were caused by PCV13 serotypes, and 1.4% and 3.3% were caused by additional serotypes included in PCV15 and PCV20, respectively (11).

^{***} Serotypes 22F and 33F, in addition to PCV13 serotypes.

^{†††} Serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to PCV13 serotypes.

^{§§§} Serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F, in addition to PCV13 serotypes.

FIGURE. Incidence of all invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine-type* invasive pneumococcal disease among adults aged ≥19 years, by invasive pneumococcal disease type and age group — United States, 2007–2019[†]



Abbreviations: IPD = invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine.

* Includes serotype 6C, which shows cross-protection from 6A antigen in PCV13 and was grouped with PCV13 serotypes for IPD incidence.

† Active Bacterial Core surveillance, 2021.

PCV15 immunogenicity. PCV15 contains pneumococcal polysaccharide serotypes 22F and 33F in addition to the PCV13 serotypes, conjugated to CRM197 (genetically detoxified diphtheria toxin) (9). Phase II and III randomized controlled trials (RCTs) evaluated the immunogenicity and safety of a dose of PCV15 compared with a dose of PCV13 in healthy adults aged ≥50 years (12–14), adults aged 18–49 years who are Native American (a population with higher rates of IPD than the general U.S. population) (15) or with ≥1 risk condition for pneumococcal disease (16), and adults aged ≥18 years with HIV infection (17). Serotype-specific functional antibody responses were measured 1 month after vaccination using an opsonophagocytic activity (OPA) assay. Correlates of protection have not been established for adults. In one phase III RCT among adults aged ≥50 years, PCV15 met the noninferiority criteria^{††††} compared with PCV13 for the 13 shared serotypes and had statistically significantly greater response^{****} for shared serotype 3 and PCV15-unique serotypes 22F and 33F (14). In studies that evaluated the immunogenicity of PCV15 or PCV13 followed by PPSV23 2–12 months later (16–18), persons who received PCV15 had numerically similar or higher OPA geometric mean antibody titers (GMTs) for 9–13^{†††††} shared PCV13 serotypes and a higher percentage of seroresponders^{§§§§} for 5–11 shared serotypes compared with persons who received PCV13 when measured 1 month after receipt of PPSV23.

PCV15 safety. Safety of PCV15 was assessed in seven RCTs with 5,630 participants aged ≥18 years who received 1 dose of PCV15. Most participants were immunocompetent; however, one study included 302 adults with HIV infection. Participants included those vaccinated with PPSV23 ≥1 year before receiving PCV15, those who received PCV15 followed by PPSV23, and those who received PCV15 concomitantly with a seasonal inactivated quadrivalent influenza vaccine (QIV). The most frequently reported adverse reactions were injection site pain, fatigue, and myalgia. The rates of serious adverse events (SAEs) within 6 months of vaccination were 2.5% among PCV15 recipients and 2.4% among PCV13 recipients. No SAEs or deaths were considered to be related to the study vaccines (9,19).

^{†††} Lower bound of the two-sided 95% CI of the OPA GMT ratio (PCV15 / PCV13) to be >0.5.

^{****} For PCV15-unique serotypes 22F and 33F, defined as the lower bound of the two-sided 95% CI of the OPA GMT ratio (V114 / PCV13) to be >2.0 and the lower bound of the two-sided 95% CI of the differences (V114 – PCV13) between the percentages of participants with a fourfold rise to be >0.1. For serotype 3, defined as the lower bound of the two-sided 95% CI of the OPA GMT ratio (V114 / PCV13) to be >1.2 and the lower bound of the two-sided 95% CI of the differences (V114 – PCV13) between the percentages of participants with a fourfold rise to be >0.

^{††††} Range reflects the difference in results across studies.

^{§§§§} Subjects with a fourfold or larger rise in OPA GMT titer postvaccination compared with prevaccination.

PCV20 immunogenicity. PCV20 contains pneumococcal polysaccharide serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to PCV13 serotypes, conjugated to CRM197 (20). A phase II study among adults aged 60–64 years and two phase III RCTs among adults aged ≥18 years evaluated immunogenicity and safety of PCV20 compared with PCV13 and with PPSV23 for the seven additional serotypes included in PCV20 (21–23). These studies included adults with stable medical conditions, but none included adults with immunocompromising conditions. Compared with PCV13 recipients, PCV20 recipients elicited responses that met noninferiority criteria^{††††} for all 13 serotypes in a phase III trial among adults aged ≥60 years (21); however, PCV20 recipients appeared to have lower GMTs and included a lower percentage of seroresponders to 12–13 of the 13 PCV13-shared serotypes (21,22). Compared with PPSV23 recipients, PCV20 recipients had numerically higher GMTs and a higher percentage of seroresponders to six of seven (excluding serotype 8) shared non-PCV13 serotypes (21,23); noninferiority criteria were met for those six serotypes (21).

PCV20 safety. Safety of PCV20 was assessed in six trials among immunocompetent adults aged ≥18 years that included a total of 4,552 participants who received PCV20. Participants included those who were naïve to pneumococcal vaccination and those who had previously received pneumococcal vaccination. The most frequently reported adverse reactions were injection site pain, muscle pain, fatigue, headache, and joint pain. SAEs reported within 6 months after vaccination occurred among 1.5% of PCV20 recipients and 1.8% among controls. No SAEs or deaths were considered to be related to study vaccines (20,24).

Intervals between PCV and PPSV23. Findings from eight immunogenicity studies that evaluated the immune response after a sequence of 7-valent PCV, PCV13, or PCV15 followed by PPSV23 administered at intervals of 2, 6, or 12 months or 3–4 years were reviewed (16–18,25–29). Three studies comparing intervals ranging from 2 to 6 months between administration of PCV and PPSV23 found no significant difference in immunogenicity measured after PPSV23 receipt, although reactogenicity tended to be higher with shorter intervals (25–29). In a study that compared antibody responses to 1 dose of PCV13 with responses to PCV13 followed by PPSV23 1 year apart, the immune responses following PPSV23 were significantly lower compared with the responses after a dose of PCV13 for eight of 12 common serotypes (27). In another study that compared antibody response to 1 dose of PCV13 with responses to PCV13 followed by PPSV23 approximately 4 years apart, the immune responses following PPSV23 were significantly higher for seven of 12 common serotypes (26).

^{††††} Defined as the lower bound of the two-sided 95% CI of the ratio (PCV20 / PCV13) of opsonophagocytic geometric mean titers being >0.5.

These findings suggested that longer intervals between administration of PCV and PPSV23 might improve immunogenicity in immunocompetent adults, although a direct comparison between a 1- versus 4-year interval was not made.

Cost-effectiveness. Economic models assessed cost-effectiveness of the new policy options compared with existing recommendations (30). Three economic models assessed PCV20 alone for all adults aged ≥ 65 years; cost-effectiveness estimates ranged from cost-saving**** to \$39,000 per quality-adjusted life-year (QALY) gained. Two economic models assessed use of PCV15 in series with PPSV23 for all adults aged ≥ 65 years; estimates ranged from cost-saving to \$282,000 per QALY gained. The CDC model found cost savings in all scenarios for use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥ 65 years. Cost estimates of policy options for adults aged 19–64 years with certain underlying medical

conditions ranged from \$11,000 to \$292,000 per QALY gained for PCV20 and from \$250,000 to \$656,000 for PCV15 in series with PPSV23.

Summary. Use of PCV20 alone or PCV15 in series with PPSV23 is expected to reduce pneumococcal disease incidence in adults aged ≥ 65 years and in those aged 19–64 years with certain underlying conditions. Findings from studies suggested that the immunogenicity and safety of PCV20 alone or PCV15 in series with PPSV23 were comparable to PCV13 alone or PCV13 in series with PPSV23. Cost-effectiveness studies demonstrated that use of PCV20 alone or PCV15 in series with PPSV23 for adults at age 65 years was cost-saving. The new policy simplifies adult pneumococcal vaccine recommendations (Table 1) and is expected to improve vaccine coverage among adults and prevent more pneumococcal disease. An amendment to recommend PCV20 for all adults aged ≥ 50 years instead of age ≥ 65 years was considered but rejected (Table 2). A summary of Work Group deliberations on use of either PCV20 alone or PCV15 in series with PPSV23 for all

**** Lower cost and improved health outcomes compared with previous recommendations.

TABLE 1. Recommendations for use of 15-valent pneumococcal conjugate vaccine in series with 23-valent pneumococcal polysaccharide vaccine or 20-valent pneumococcal conjugate vaccine in pneumococcal conjugate vaccine-naïve adults aged ≥ 19 years — United States, 2022

Medical indication group	Specific underlying medical condition	Age group, yrs	
		19–64	≥ 65
None	None	None	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 1 years later*
Underlying medical conditions or other risk factors	Alcoholism Chronic heart disease† Chronic liver disease Chronic lung disease¶ Cigarette smoking Diabetes mellitus Cochlear implant CSF leak Congenital or acquired asplenia** Sickle cell disease or other hemoglobinopathies** Chronic renal failure** Congenital or acquired immunodeficiencies**,†† Generalized malignancy** HIV infection** Hodgkin disease** Iatrogenic immunosuppression**,§§ Leukemia** Lymphoma** Multiple myeloma** Nephrotic syndrome** Solid organ transplant**	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 1 years later§	1 dose of PCV20 or 1 dose of PCV15 followed by a dose of PPSV23 ≥ 1 years later*

Abbreviations: CSF = cerebrospinal fluid; PCV15 = 15-valent pneumococcal conjugate vaccine; PCV20 = 20-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

* Adults with immunocompromising conditions, cochlear implant, or CSF leak might benefit from shorter intervals such as ≥ 8 weeks. These vaccine doses do not need to be repeated if given before age 65 years.

† Includes congestive heart failure and cardiomyopathies.

‡ Adults with immunocompromising conditions, cochlear implant, or CSF leak might benefit from shorter intervals such as ≥ 8 weeks.

¶ Includes chronic obstructive pulmonary disease, emphysema, and asthma.

** Indicates immunocompromising conditions.

†† Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

§§ Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.

adults aged ≥65 years or adults aged 19–64 years with certain underlying conditions is available in the EtR tables.

New Pneumococcal Vaccine Recommendations

Adults aged ≥65 years. Adults aged ≥65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23 (Table 1).

Adults aged 19–64 years with certain underlying medical conditions or other risk factors. Adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

Clinical Guidance

Dosing schedule. When PCV15 is used, the recommended interval between administration of PCV15 and PPSV23 is ≥1 year. A minimum interval of 8 weeks can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak to minimize the risk for IPD caused by serotypes unique to PPSV23 in these vulnerable groups (31).

Adults with previous PPSV23 only. Adults who have only received PPSV23 may receive a PCV (either PCV20 or PCV15) ≥1 year after their last PPSV23 dose. When PCV15 is used in those with history of PPSV23 receipt, it need not be followed by another dose of PPSV23.

Adults with previous PCV13. The incremental public health benefits of providing PCV15 or PCV20 to adults who have received PCV13 only or both PCV13 and PPSV23 have not been evaluated. These adults should complete the previously recommended PPSV23††††† series (2,30).

Coadministration with other vaccines. PCV15, PCV20, or PPSV23 can be coadministered with QIV in an adult immunization program, as concomitant administration (PCV15 or PPSV23 and QIV [Fluarix], PCV20 and adjuvanted QIV [Fluad]) has been demonstrated to be immunogenic and safe. However, slightly lower pneumococcal serotype-specific OPA GMTs or geometric mean concentrations were reported when pneumococcal vaccines were coadministered with QIV compared with when pneumococcal vaccines were given alone (9,19,32,33). Currently, no data are available on coadministration with other vaccines (e.g., tetanus, diphtheria, acellular pertussis vaccine, hepatitis B, or zoster vaccine) among adults. Evaluation of coadministration of PCV15, PCV20, or PPSV23 with COVID-19 vaccines is ongoing (34,35).

Future Research and Monitoring Priorities

CDC and ACIP will continue to assess safety of PCV15 and PCV20 vaccines, monitor the impact of implementation of new recommendations, and assess postimplementation vaccine effectiveness and update pneumococcal vaccination recommendations as appropriate.

††††† For adults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available.

TABLE 2. Age-based policy options for use of 15-valent pneumococcal conjugate vaccine or 20-valent pneumococcal conjugate vaccine in adults presented for a vote and considerations by the Advisory Committee on Immunization Practices — United States, October 2021

Proposed policy	Considerations raised during October 2021 ACIP meeting in favor of the option	Outcome (votes in favor: against)
Adults aged ≥50 years who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.	Might reduce existing pneumococcal disease disparity in adults aged 50–64 years. Age-based recommendation is easier to implement than risk-based recommendation. Might provide more opportunities to vaccinate adults before underlying conditions develop.	Rejected (4:11)
Adults aged ≥65 years who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.	Potential for waning vaccine-induced immunity makes it favorable to vaccinate later in life when risk for disease is higher. Consistently cost saving in cost-effectiveness analyses. Still provides an opportunity for higher PCV coverage in adults compared with current recommendations. No evidence that lowering the age-based recommendation will reduce disparity in vaccine-preventable disease compared with risk-based recommendations.	Affirmed (15:0)

Abbreviations: ACIP = Advisory Committee on Immunization Practices; PCV = pneumococcal conjugate vaccine; PCV15 = 15-valent PCV; PCV20 = 20-valent PCV; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

Summary**What is already known about this topic?**

Currently, the 13-valent pneumococcal conjugate vaccine (PCV) (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for U.S. adults. Recommendations vary by age and risk groups.

What is added by this report?

On October 20, 2021, the Advisory Committee on Immunization Practices recommended 15-valent PCV (PCV15) or 20-valent PCV (PCV20) for PCV-naïve adults who are either aged ≥65 years or aged 19–64 years with certain underlying conditions. When PCV15 is used, it should be followed by a dose of PPSV23, typically ≥1 year later.

What are the implications for public health practice?

Pneumococcal vaccination recommendations were simplified across age and risk group. Eligible adults may receive either PCV15 in series with PPSV23 or PCV20 alone.

Foundation; Rebecca L. Morgan, McMaster University; Arthur Reingold, University of California, Berkeley; Lorry Rubin, Cohen Children's Medical Center of Northwell Health; Cynthia Whitney, Emory University; Richard K. Zimmerman, University of Pittsburgh. Marc Fischer, Penina Haber, Pedro Moro, Sarah Schillie, CDC.

Corresponding author: Miwako Kobayashi, mkobayashi@cdc.gov, 404-639-2215.

¹National Center for Immunization and Respiratory Diseases, CDC; ²Epidemic Intelligence Service, CDC; ³CDC Foundation; ⁴University of Arizona, College of Medicine, Phoenix, Arizona; ⁵Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario; ⁶Drexel University College of Medicine, Philadelphia, Pennsylvania; ⁷Vanderbilt University School of Medicine, Nashville, Tennessee; ⁸Wake Forest School of Medicine, Winston-Salem, North Carolina.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Katherine A. Poehling reports institutional support from Safe Sleep for All Newborns, Love Out Loud Early Childhood Fellowship, Intimate Partner Violence Collaborative Project, Because You Matter: Conversations You Want about COVID-19, text messaging follow-up for patients who missed well child visits, and Reimagining Health and Wellness by Mothers for Our Babies, Families, and Communities. H. Keipp Talbott reports institutional grants from the National Institutes of Health. No other potential conflicts of interest were disclosed.

References

1. CDC; Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102–6. PMID:20814406
2. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816–9. PMID:23051612
3. Tomczyk S, Bennett NM, Stoecker C, et al.; CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822–5. PMID:25233284
4. Childs L, Kobayashi M, Farrar JL, Pilishvili T. The efficacy and effectiveness of pneumococcal vaccines against pneumococcal pneumonia among adults: a systematic review and meta-analysis. Open Forum Infect Dis 2021;8(Supp 1):S130–1. <https://doi.org/10.1093/ofid/ofab466.215>
5. Farrar JL, Kobayashi M, Childs L, Pilishvili T. Systematic review and meta-analysis of pneumococcal vaccine effectiveness against invasive pneumococcal disease among adults. Open Forum Infect Dis 2021;8(Supp 1):S134–5. <https://doi.org/10.1093/ofid/ofab466.223>
6. Suzuki M, Dhoubhadel BG, Ishifuri T, et al.; Adult Pneumonia Study Group-Japan (APSG-J). Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis 2017;17:313–21. PMID:28126327 [https://doi.org/10.1016/S1473-3099\(17\)30049-X](https://doi.org/10.1016/S1473-3099(17)30049-X)

7. Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. *PLoS Med* 2020;17:e1003326. PMID:33095759 <https://doi.org/10.1371/journal.pmed.1003326>
8. Kim JH, Chun BC, Song JY, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. *Vaccine* 2019;37:2797–804. PMID:31005428 <https://doi.org/10.1016/j.vaccine.2019.04.017>
9. VAXNEUVANCE. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. <https://www.fda.gov/media/150819/download>
10. McLaughlin JM, Khan FL, Thoburn EA, Isturiz RE, Swerdlow DL. Rates of hospitalization for community-acquired pneumonia among US adults: a systematic review. *Vaccine* 2020;38:741–51. PMID:31843272 <https://doi.org/10.1016/j.vaccine.2019.10.101>
11. Isturiz R, Grant L, Gray S, et al. Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults. *Clin Infect Dis* 2021;73:1216–22. PMID:33982098 <https://doi.org/10.1093/cid/ciab375>
12. Ermlich SJ, Andrews CP, Folkerth S, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. *Vaccine* 2018;36:6875–82. PMID:29559167 <https://doi.org/10.1016/j.vaccine.2018.03.012>
13. Peterson JT, Stacey HL, MacNair JE, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Hum Vaccin Immunother* 2019;15:540–8. PMID:30427749 <https://doi.org/10.1080/21645515.2018.1532250>
14. Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). *Vaccine* 2022;40:162–72. PMID:34507861 <https://doi.org/10.1016/j.vaccine.2021.08.049>
15. Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, Hennessy TW. The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations. *Vaccine* 2011;29:5355–62. PMID:21664217 <https://doi.org/10.1016/j.vaccine.2011.05.086>
16. Merck Sharp & Dohme Corp. A study to evaluate the safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX™23 in adults at increased risk for pneumococcal disease (V114–017/PNEU-DAY). Bethesda, MD: US National Library of Medicine; 2021. <https://ClinicalTrials.gov/show/NCT03547167>
17. Mohapi L, Pinedo Y, Osiyemi O, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study. *AIDS* 2021. Epub November 22, 2021. https://journals.lww.com/aidsonline/Abstract/9000/Safety_and_immune/immunogenicity_of_V114,_a_15_valent.96271.aspx
18. Song JY, Chang CJ, Andrews C, et al.; V114-016 (PNEU-PATH) study group. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). *Vaccine* 2021;39:6422–36. PMID:34489128 <https://doi.org/10.1016/j.vaccine.2021.08.038>
19. Food and Drug Administration. Summary basis for regulatory action—VAXNEUVANCE. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. <https://www.fda.gov/media/151201/download>
20. PREVNAR 20. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. <https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20>
21. Essink B, Sabharwal C, Xu X, et al. 3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. *Open Forum Infect Dis* 2020;7(Supplement_1):S2. <https://doi.org/10.1093/ofid/ofaa417.002>
22. Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 18 through 49 years of age. *Vaccine* 2021;39:5428–35. PMID:34315611 <https://doi.org/10.1016/j.vaccine.2021.07.004>
23. Hurley D, Griffin C, Young M Jr, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. *Clin Infect Dis* 2021;73:e1489–97. PMID:32716500 <https://doi.org/10.1093/cid/ciaa1045>
24. Food and Drug Administration. Summary basis for regulatory action—PREVNAR20. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, 2021. <https://www.fda.gov/media/150388/download>
25. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska Native adults 55–70 years of age. *Clin Infect Dis* 2009;49:241–8. PMID:19522655 <https://doi.org/10.1086/599824>
26. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. *Vaccine* 2013;31:3594–602. PMID:23688525 <https://doi.org/10.1016/j.vaccine.2013.04.084>
27. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. *Vaccine* 2014;32:2364–74. PMID:24606865 <https://doi.org/10.1016/j.vaccine.2014.02.002>
28. Buchwald UK, Andrews CP, Ervin J, et al.; V110–029 Study Group. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. *Hum Vaccin Immunother* 2021;17:2678–90. PMID:34019468 <https://doi.org/10.1080/21645515.2021.1888621>
29. Nguyen MTT, Lindegaard H, Hendricks O, Jørgensen CS, Kantsø B, Friis-Møller N. Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial. *J Rheumatol* 2017;44:1794–803. PMID:28966211 <https://doi.org/10.3899/jrheum.161407>
30. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2019;68:1069–75. PMID:31751323 <https://doi.org/10.15585/mmwr.mm6846a5>
31. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2015;64:944–7. PMID:26334788 <https://doi.org/10.15585/mmwr.mm6434a4>
32. Pfizer. Safety and immunogenicity of 20vPnC coadministered with SIV in adults ≥65 years of age. Bethesda, MD: US National Library of Medicine; 2020. <https://ClinicalTrials.gov/show/NCT04526574>

33. Ofori-Anyinam O, Leroux-Roels G, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: results from a phase III, randomized, non-inferiority trial. *Vaccine* 2017;35:6321–8. PMID:28987445 <https://doi.org/10.1016/j.vaccine.2017.09.012>
34. Pfizer. Safety and immunogenicity study of 20vPnC when coadministered with a booster dose of BNT162b2. Bethesda, MD: US National Library of Medicine; 2021. <https://clinicaltrials.gov/ct2/show/NCT04887948>
35. Merck Sharp & Dohme Corp. Safety, tolerability, and immunogenicity of V110 or V114 co-administered with a booster dose of mRNA-1273 in healthy adults (V110-911). Bethesda, MD: US National Library of Medicine; 2021. <https://ClinicalTrials.gov/show/NCT05158140>
36. Food and Drug Administration. PNEUMOVAX23. Package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020. <https://www.fda.gov/vaccines-blood-biologics/vaccines/pneumovax-23-pneumococcal-vaccine-polyvalent>